By Fineline Cube 
China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) has entered into a commercialization partnership with Beijing Jiluntai Pharmaceutical Co., Ltd (Radio technology). Under the agreement, Baheal secures the rights to commercialize Jiluntai’s Category 1 nuclear pharmaceutical drug, Technetium-99m-labeled hydrazinylnicotinamide-polyethylene glycol-bicyclic RGD peptide, in mainland China.
Partnership Terms and Financials
Baheal will pay Jiluntai a licensing fee of up to RMB 50 million (USD 6.9 million) in installments. The agreement includes a refund clause: if the product fails to obtain marketing approval from the National Medical Products Administration (NMPA) by June 30, 2026, Baheal will receive a refund of the licensing fee plus any accrued interest.
Product Innovation and Clinical Progress
Jiluntai’s Technetium-99m-labeled hydrazinylnicotinamide-polyethylene glycol-bicyclic RGD peptide is recognized as the world’s first broad-spectrum tumor imaging agent for SPECT imaging. The drug has demonstrated significant promise in its Phase III clinical trials, achieving both primary and secondary endpoints. This innovation underscores the potential for advancing tumor detection and diagnosis through advanced imaging technologies.-Fineline Info & Tech